ADVIA CENTAUR XPT PSA ASSAY N/A 10310292

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a foreign,health professional,u report with the FDA on 2018-01-29 for ADVIA CENTAUR XPT PSA ASSAY N/A 10310292 manufactured by Siemens Healthcare Diagnotics, Inc.

Event Text Entries

[101976733] Based on an evaluation of the customer's results, this sample is a hook sample, however, siemens has requested the sample for further evaluation. The procedural notes high-dose hook effect section of the instructions for use (ifu) states the following: "patient samples with high total psa levels can cause a paradoxical decrease in the rlus (high-dose hook effect). In this assay, patient samples with total psa levels as high as 10,000 ng/ml (10,000 ug/l) will assay greater than 100 ng/ml (100 ug/l). " siemens issued urgent field corrective action cc 16-05. A. Ous and urgent medical device correction cc 16-05. A. Us on december 2015 informing the customer that the advia centaur systems prostate specific antigen (psa) assay kit lots ending in 263 and above are not meeting the current high-dose hook effect expectation in the instructions for use (ifu). Instructions on actions to be taken are provided in the customer communication. The sample was run neat on first presentation via aptio automation, then via the centralink trigger for all psa sample results >=40ug/l, the sample was repeated 1/5; then 1/10 then 1/50. After the last centralink automated dilution, the sample was routed by the trigger to the delivery sort lane on aptio for manual operator intervention. However, the operator simply placed the sample back into rerun in centralink without ordering a higher dilution as per laboratory protocol and the neat result was reported. The intended use section of the ifu states the following: "this in vitro diagnostic assay is intended to quantitatively measure prostate-specific antigen (psa) in human serum using the advia centaur and advia centaur xp systems. This assay is indicated for the measurement of serum psa in conjunction with digital rectal exam (dre) as an aid in the detection of prostate cancer in men aged 50 years and older. This assay is further indicated as an aid in the management (monitoring) of patients with prostate cancer. " the limitation section of the ifu states the following: " warning" "do not predict disease recurrence solely on serial psa values. " "do not interpret levels of psa as absolute evidence of the presence or the absence of malignant disease. Before treatment, patients with confirmed prostate carcinoma frequently have levels of psa within the range observed in healthy individuals. Elevated levels of psa can be observed in patients with nonmalignant diseases. Measurements of psa should always be used in conjunction with other diagnostic procedures, including information from the patient's clinical evaluation. "
Patient Sequence No: 1, Text Type: N, H10


[101976734] Customer observed a low advia centaur xpt psa result that was higher upon dilution. The low result was reported to the physician who questioned the result. There are no reports that treatment was altered or prescribed or adverse health consequences due to the low advia centaur psa result.
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report Number1219913-2018-00106
MDR Report Key7320039
Report SourceFOREIGN,HEALTH PROFESSIONAL,U
Date Received2018-01-29
Date of Report2018-01-29
Date of Event2018-01-04
Date Mfgr Received2018-04-10
Device Manufacturer Date2017-05-03
Date Added to Maude2018-03-07
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag0
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactLOUISE MCLAUGHLIN
Manufacturer Street333 CONEY STREET
Manufacturer CityEAST WALPOLE MA 02032
Manufacturer CountryUS
Manufacturer Postal02032
Manufacturer Phone5086604381
Manufacturer G1SIEMENS HEALTHCARE DIAGNOSTICS, INC
Manufacturer Street333 CONEY STREET
Manufacturer CityEAST WALPOLE MA 02032
Manufacturer CountryUS
Manufacturer Postal Code02032
Single Use3
Remedial ActionNO
Previous Use Code3
Removal Correction Number1219913-12/30/2015-004-C
Event Type3
Type of Report3

Device Details

Brand NameADVIA CENTAUR XPT PSA ASSAY
Generic NamePSA IMMUNOOASSY
Product CodeMTF
Date Received2018-01-29
Model NumberN/A
Catalog Number10310292
Lot Number95782281
Device Expiration Date2018-05-03
OperatorHEALTH PROFESSIONAL
Device AvailabilityN
Device AgeDA
Device Eval'ed by MfgrR
Device Sequence No1
Device Event Key0
ManufacturerSIEMENS HEALTHCARE DIAGNOTICS, INC
Manufacturer Address511 BENEDICT AVENUE TARRYTOWN NY 105915097 US 105915097


Patients

Patient NumberTreatmentOutcomeDate
10 2018-01-29

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.